

CENTRAL ASIAN JOURNAL OF MEDICAL AND NATURAL SCIENCES
https://cajmns.centralasianstudies.org/index.php/CAJMNS
Volume: 05 Issue: 02 | April 2024 ISSN: 2660-4159

A Review Article

Diabesity Effects on Fetuin- A, Adiponectin and Leptin

Noor Alhuda Kh Ibrahim[1*], Shahad F. Obeid[2], Wasnaa J. Mohammad[1]

1. University of Baghdad, College of Nursing, Department of Basic Sciences, Baghdad, Iraq
* Correspondence: noorkh@conursing.uobaghdad.edu.iq
2. University of Baghdad, College of Sciences, Department of Chemistry, Baghdad, Iraq

Abstract: An increasing amount of epidemiological research connects liver function to excessive weight and its aftereffects, that also diabetes and metabolic illness. Experiments showed a elaborate system of connections in relation to liver and fat storage that mutually regulate their respective activities, in line with human findings. The main mediators of this connection are hormone/cytokine signals located in the fat (adiponectin and leptin) and the liver (fetuin-A). We will discuss the latest advancements in our comprehension of the processes underpinning the interaction in relation to the liver and adipose tissue that puts individuals at risk for diabetes, obesity, and other health problems. Increased fetuin-A degrees are link to grow likelihood of developing type two diabetes and the metabolic illness. Adiponectin deficiency is associated with multiple illnesses, that also atherosclerosis, type 2 diabetes as well as body fat. Hyperglycemia and hyperinsulinemia, which result from inadequate leptin signaling in the hypothalamus (produced by hyperleptinemia in obese individuals), are the primary causes of diabetes mellitus.

Keywords: obesity, fetuin-A, leptin, adiponectin, diabetes

1. Introduction

Due to the increase in bad lifestyle choices that have become more common in the second half of the last century, such as consuming an excessive amount of processed foods and not exercising, obesity has spread around the world throughout the last three decades. As a result, a wave of over fifty obesity-related issues has surfaced, endangering the health and welfare of people everywhere. Currently, 800 million people worldwide suffer from obesity, and by 2025, it is projected that healthcare costs associated with obesity-related illnesses will total one trillion US dollars 2022 [1]. Additionally, it is anticipated that by 2030, 250 million children will be obese. Until health officials and agencies create a huge worldwide action plan to stop the excessive weight pandemic, this represents probably going to have a big impact on people's lives and healthcare systems for a while to come.

Type two diabetes mellitus (T2DM) is the most lethal metabolic consequence of obesity, which dramatically raises the risk of death and disability caused by arterial disease. Additional health complications caused by obesity might worsen symptoms including dyslipidemia, high blood pressure, metabolic-associated fatty liver disease (MAFLD), sleep apnea, heart failure, ischemic heart disease, cancer, and osteoarthritis. This is particularly true for people who suffer from type 2 diabetes. Sims and associates (1970s) [2] first used the word "diabesity" to characterize the significant connection between diabetes and

Citation: Ibrahim, N. A. K., Obeid, S. F., & Mohammad, W. J. Diabesity Effects on Fetuin- A, Adiponectin and Leptin. Central Asian Journal of Medical and Natural Science 2024, 5(2), 166-171.

Received: 3rd April 2024
Revised: 10th April 2024
Accepted: 17th April 2024
Published: 24th April 2024

obesity from a pathophysiological standpoint. One theory is that insulin resistance, a consequence of visceral fat, contributes to the onset of diabetes mellitus. Thus, optimal management should also be a part of the disease's ideal treatment plan of fat 2019 [3].

Nonalcoholic fatty liver disease, or NAFLD for short, is a liver disease which may have an impact on those who abstain from alcohol altogether. For NAFLD, the liver collects an excessive amount of fat. The people who experience it most frequently are those on the verge of being overweight 2023 [4].

NAFLD rising at an increasing rate commonplace worldwide as the number of obese individuals rises, especially in Western and Middle Eastern nations. It affects about 25% of people globally This accounts for the vast majority of cases of long-term liver damage. In the US, NAFLD affects about 100 million people 2023 [4].

Circulating phosphorylated and dephosphorylated forms of fetuin-A (Fet-A), a hepatokine that are linked to obesity, insulin resistance, and type 2 diabetes incidence, previously demonstrated. Research on the functional significance of fetuin-A phosphorylation status in insulin-resistant conditions is, however, scarce 2019 [5]. Circulating phosphorylated and dephosphorylated forms of fetuin-A (Fet-A), a hepatokine associated with obesity, insulin resistance, and type 2 diabetes incidence, previously demonstrated. Research on the functional significance of fetuin-A phosphorylation status in insulin-resistant conditions is, however, scarce 2020 [6].

Tumour necrosis factor alpha is an inflammatory cytokine that monocytes and macrophages release, which causes acute inflammation. It sets off a range of signaling reactions in cells that cause the either apoptosis or necrosis. Additionally, the protein is critical for cancer 2000 and infection resistance [7]. Adipose tissue secretes a peptide hormone called leptin, which is encoded by the obese (ob) gene. Although leptin's involvement in the control of hunger, neuroendocrine function, and energy homeostasis is well-established, it also appears to have an impact on a number of other physiological processes 2023 [8].

Seven trials totaling 11,497 people and 2176 incidences of T2DM were taken into consideration for the systematic review and meta-analysis. All things considered, each SD rise in fetuin-A level was involved with a 23% higher danger of occurrence type 2 diabetes. Neither significant heterogeneity nor obvious publication bias were present. The association between the different categories stayed rather stable. However, the association did not seem to exist in men; it only seemed to exist in women. An increased risk of type 2 diabetes is believed to have links to elevated levels of circulating fetuin-A 2018 [9]. The incidence of diabetes and plasma fetuin-A levels correlated positively, even when age was taken into account. The association was substantial even after controlling for waist circumference, BMI, sex, and lifestyle risk factors. This result stayed largely unaltered 2008 [10].

The glycoprotein Fetuin-A is released via fat storage and the liver, together with a 64 kDa molecular weight. Elevated blood levels of Fet-A are linked to obesity, type 2 diabetes mellitus, metabolic illness, and nonalcoholic fatty liver disease. In addition, Caliciprotein particle, a Fet-A-related marker, is substantially linked with vascular calcification in overweight/obese patients with chronic renal illness. Insulin resistance and impaired glucose tolerance are other outcomes associated with elevated foetal A levels. An increasing body of research suggests that elevating Fetuin A leads to poor glycemic control since Fet-A has been connected to impaired insulin receptor signaling, toll-like receptor 4 activation, macrophage migration and polarization, adipocyte dysfunction, hepatocyte triacylglycerol accumulation, liver inflammation and fibrosis, and adipocyte dysfunction. It's been shown that reducing fetuin A can be achieved with metformin, pioglitazone, weight loss, and aerobic exercise 2015 [11].

Nowadays, diabetes is becoming a bigger issue for older people. Diabetes treatment and prevention are top priorities for global health. Adiponectin is a protein hormone generated from adipocytes that improves insulin sensitivity and mitigates the symptoms of diabetes by stimulating skeletal muscle glucose absorption and oxidation of fatty acids

while decreasing the liver's synthesis of glucose. Metabolic syndrome, insulin resistance, diabetes, and central obesity are linked to low serum adiponectin concentrations 2021 [12]. On chromosome 3q27, the adiponectin gene is located, along with a locus connected to the risk of diabetes. Adiponectin gene (ADIPOQ) single nucleotide polymorphisms (SNPs) they've been linked to diabetes in multiple cross-sectional studies. SNPs within ADIPOQ aid in determining how common variations relate to adiponectin levels and diabetes risk. The two frequent SNPs, rs1501299 and rs2241766, exhibited a substantial correlation with type 1 diabetes mellitus, which results in a block of haplotypes that are universally present. There is a substantial correlation between rs1501299, rs2241766, rs266729, rs17366743, rs17300539, rs182052, rs822396, rs17846866, rs3774261 and rs822393 and the disease's common form, type 2 diabetes mellitus. There is experimental data to support these conclusions. Moreover, rs2241766 and rs266729 have a substantial association Throughout pregnancy, a disease that impacts expectant mothers. Therefore, Multiple single-nucleotide polymorphisms (SNPs) in the adiponectin gene, rather than a single mutation, may increase the risk of diabetes in people all over the globe. Adiponectin has a pathophysiological influence on type 1, type 2, and gestational diabetes mellitus, as revealed conclusively by this research 2021 [12].

The fall in adiponectin levels and markers of persistent subclinical inflammation are negatively correlated with obesity. Adipocyte hypertrophy is the cause of both metabolic syndrome and insulin resistance, which are linked to obesity. Furthermore, in obese people, macrophage polarization is essential for regulating the expression of the adiponectin receptor (AdipoR1/R2) and the different ways in which macrophages respond to adiponectin-mediated inflammation. Declining AdipoR1/R2 mRNA expression causes adiponectin binding to the cell membrane to diminish, which in turn causes adiponectin concentrations to plummet [13]. This attenuates the effects of adiponectin. Leucine zipper motif 1 (APPL1), phosphotyrosine-binding domain, and pleckstrin homology domain of adaptor proteins are the intracellular binding partners of AdipoR1 and AdipoR2 within the receptor complex. Adiponectin activity varies in response to variations in APPL1 or APPL2 expression. Adiponectin's action and efficacy can be altered by APPL1/APPL2-induced decreased Post receptor signaling, even in cases where adiponectin levels are high or normal. Despite that, APPL2 blocks adiponectin signaling through AdipoR1 and AdipoR2 by competitively inhibiting APPL1 2017 [13]. APPL1 is another important regulator of insulin sensitivity that is dependent on adiponectin. Here, adiponectin resistance and insulin resistance are associated, with the latter being partly attributed to the low regulation of adiponectin receptors in those given a high-fat diet. In reality, after eating a diet elevated with saturated fat, adiponectin resistancy occurs rapidly; this metabolic disruption is not brought on by a drop in the amount of AdipoR1 protein. Obesity causes a decrease in AdipoR2 expression in intra-abdominal adipose tissue but not AdipoR1 expression. Insulin resistance and adiponectin resistance combine to create a vicious cycle. A compensating reaction in cases of increased adiponectin levels and adiponectin resistance the state in which adiponectin insensitivity and insulin resistance exhibit an uncommon discrepancy 2017 [13].

Considered collectively, Long-term high blood sugar levels caused by an insulin resistance disease known as diabetic mellitus, production, one or the other. Ninety percent cases of D.M. are type 2, which leads to micro and macrovascular problems that are physically and psychologically distressing as well as a significant cost on the healthcare system and providers. Body fat percentage and BMI are correlated with elevated levels of leptin, which are typically present in obese individuals. Even Nevertheless, there is a relationship between leptin and BMI. The factor that had the strongest correlation with leptin in men was BMI. AIM: The purpose of this 2020 research was to examine leptin's potential involvement in the development of obesity and type 2 diabetes [14]. In light of this, suggestive signals blood samples were used to evaluate the prevalence of type 2 diabetes mellitus and obesity, and a connection with leptin was noted. A hospital in India, a cross-sectional observational study was planned to run for a year. The study included physical examinations,

laboratory analyses, and in-person questionnaire interviews. In the 200 subjects that were included in the current research, 50 were male and the remaining 50 were female [14]. Additionally, 100 controls were added. Standard protocols were adhered to in the measurement of anthropometric data. Biochemical analyses were conducted using the appropriate methodology for every parameter. The age of the individuals was 55.34 ± 2.43 Yrs, with 64% of them falling between the 40–60 age range. 56 % of the whole the subject's BMI is more than 30. The cases group had higher leptin levels than the controls, because there was a statistically significant disparity ($p<0.0001$).According to the study's findings, patients with diabetes had considerably higher serum leptin levels than the healthy control group, who did not have diabetes [14]. In addition to controlling food intake, body mass, and reproductive processes, the peptide hormone leptin also affects angiogenesis, lipolysis, proinflammatory immune responses, and fetal growth. The hormone leptin, which is produced by the obese gene, attaches to and activates the leptin receptor. LEP-R distribution mediates the variety of impacts of leptin and is necessary for controlling weight by use of a negative feedback loop where the hypothalamus and adipose tissue interact [15]. Increased total body mass, overindulgence in food, and decreased satiety are signs of leptin resistance. Obesity, which commonly results from this, decreases the therapeutic efficacy of outside-the-body leptin. Thus, combining leptin sensitizers together with the hormone leptin therapies could be beneficial reduce obesity caused by resistance to leptin 2021 [15].

2. Discussion

The several data sets clearly confirm that fetuin-A, a liver-secreted protein, reduces and inhibits the process by which fat cells produce adiponectin. This lends credence to the theory that insulin resistance brought on by fat and the development of diabetes may be significantly influenced by elevated hepatokine levels of fetuin-A and decreased adiponectin 2008 [16]. Since it is one of the main causes of type 2 diabetes and an insulin sensitizer derived from adipose tissue, when it comes to the connection between obesity and insulin resistance, adiponectin plays a significant role. Lower levels of adiponectin were observed ten years before type 2 diabetes was identified 2012 [17]. Obesity, Type 2 diabetes, and atherosclerosis are a few conditions associated with low adiponectin levels 2022 [18].

Leptin receptors on central nervous system neurons mediate leptin's effects on hunger and fat storage. These signals allow energy expenditure while suppressing food intake. Additionally, pro-opiomelanocortin (POMC) mediates leptin`s effect on obesity and resistancy of insulin 2012 [19]. Because obesity causes insulin resistance and β-cell malfunction, having type 2 diabetes becomes more likely and prediabetes. When obesity is coupled with increased triglyceride levels in the liver and muscles, this becomes much more evident, as well as increased intra-abdominal and abdominal fat distribution 2012 [20].

Adiponectin levels may also be a factor in why some fat persons do not develop diabetes. It is possible that adiponectin shields against the metabolic abnormalities that leads to DMII among certain obese people 2017 [21].

3. Conclusion

Developing type 2 diabetes is more likely and the metabolic illness is linked with elevated fetuin-A levels. Low levels of the protein adiponectin has been linked to several health problems, such as obesity, diabetes type 2, and atherosclerosis. Obese people's hyperleptinemia causes inadequate hypothalamic leptin signaling, which in turn causes hyperglycemia and hyperinsulinemia, which in turn cause diabetes mellitus.

REFERENCES

[1] "Obesity fact sheet," World Obesity Day 2022.

[2] E. A. H. Sims, E. D. Jr, E. S. Horton, G. A. Bray, and ..., "Endocrine and metabolic effects of experimental obesity in man," *Proceedings of the 1972 …*, 1973, [Online]. Available: https://www.sciencedirect.com/science/article/pii/B9780125711296500166

[3] J. M. Pappachan, C. J. Fernandez, and E. C. Chacko, "Diabesity and antidiabetic drugs," *Mol Aspects Med*, 2019, [Online]. Available: https://www.sciencedirect.com/science/article/pii/S0098299718300840

[4] "Nonalcoholic Fatty Liver Disease (NAFLD)," American Liver Foundation. https://liverfoundation.org/liver-diseases/fatty-liver-disease/nonalcoholic-fatty-liver-disease-nafld. Accessed May 11, 2023.

[5] G. Ren, T. Kim, J. B. Papizan, and ..., "Phosphorylation status of fetuin-A is critical for inhibition of insulin action and is correlated with obesity and insulin resistance," *… Journal of …*, 2019, doi: 10.1152/ajpendo.00089.2018.

[6] T. M. D. Nguyen, "Adiponectin: role in physiology and pathophysiology," *Int J Prev Med*, 2020, [Online]. Available: https://journals.lww.com/ijom/fulltext/2020/11000/Adiponectin__Role_in_Physiology_and.9.aspx

[7] H. T. Idriss and J. H. Naismith, "TNF alpha and the TNF receptor superfamily: structure-function relationship (s) Microsc Res Tech. 2000; 50 (3): 184–195. doi: 10.1002/1097-0029 …," *Co*.

[8] S. Dornbush and N. R. Aeddula, *Physiology, leptin*. europepmc.org, 2019. [Online]. Available: https://europepmc.org/article/nbk/nbk537038

[9] V. Y. Guo, B. Cao, C. Cai, K. K. Cheng, and B. M. Y. Cheung, "Fetuin-A levels and risk of type 2 diabetes mellitus: a systematic review and meta-analysis," *Acta Diabetol*, 2018, doi: 10.1007/s00592-017-1068-9.

[10] N. Stefan, A. Fritsche, C. Weikert, H. Boeing, H. G. Joost, and ..., "Plasma fetuin-A levels and the risk of type 2 diabetes," *Diabetes*, 2008, [Online]. Available: https://diabetesjournals.org/diabetes/article-abstract/57/10/2762/13362

[11] J. F. Trepanowski, J. Mey, and K. A. Varady, "Fetuin-A: a novel link between obesity and related complications," *Int J Obes*, 2015, [Online]. Available: https://www.nature.com/articles/ijo2014203

[12] M. Howlader, M. I. Sultana, F. Akter, and M. M. Hossain, "Adiponectin gene polymorphisms associated with diabetes mellitus: A descriptive review," *Heliyon*, 2021, [Online]. Available: https://www.cell.com/heliyon/pdf/S2405-8440(21)01954-X.pdf

[13] A. Engin, "Adiponectin-resistance in obesity," *Obesity and lipotoxicity*, 2017, doi: 10.1007/978-3-319-48382-5_18.

[14] R. Ambad, R. K. Jha, D. H. Chandi, and ..., "Association of leptin in diabetes mellitus and obesity," *Research Journal of …*, 2020, [Online]. Available: https://www.indianjournals.com/ijor.aspx?target=ijor:rjpt&volume=13&issue=12&article=110

[15] M. Obradovic, E. Sudar-Milovanovic, S. Soskic, and ..., "Leptin and obesity: role and clinical implication," *Frontiers in …*, 2021, doi: 10.3389/fendo.2021.585887.

[16] A. M. Hennige, H. Staiger, C. Wicke, F. Machicao, and ..., "Fetuin-A induces cytokine expression and suppresses adiponectin production," *PLoS One*, 2008, [Online]. Available: https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0001765

[17] A. G. Tabák, M. Carstensen, D. R. Witte, E. J. Brunner, and ..., "Adiponectin trajectories before type 2 diabetes diagnosis: Whitehall II study," *Diabetes …*, 2012, [Online]. Available: https://diabetesjournals.org/care/article-abstract/35/12/2540/38570

[18] A. E. Achari and S. K. Jain, "Adiponectin, a therapeutic target for obesity, diabetes, and endothelial dysfunction," *Int J Mol Sci*, 2017, [Online]. Available: https://www.mdpi.com/1422-0067/18/6/1321

[19] R. Coppari and C. Bjørbæk, "Leptin revisited: its mechanism of action and potential for treating diabetes," *Nat Rev Drug Discov*, 2012, [Online]. Available: https://www.nature.com/articles/nrd3757

[20] S. Klein, A. Gastaldelli, H. Yki-Järvinen, and P. E. Scherer, "Why does obesity cause diabetes?," *Cell Metab*, 2022, [Online]. Available: https://www.cell.com/cell-metabolism/pdf/S1550-4131(21)00631-8.pdf

[21] A. E. Achari and S. K. Jain, "Adiponectin, a therapeutic target for obesity, diabetes, and endothelial dysfunction," *Int J Mol Sci*, 2017, [Online]. Available: https://www.mdpi.com/1422-0067/18/6/1321